search results for 
Logo

3. Special items

The consolidated statement of income for the year 2011 ultimately includes several special items relating to the acquisition of APP Pharmaceuticals, Inc. in 2008. The tables below reconcile adjusted earnings to earnings according to U.S. GAAP in 2011 and 2010.

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2011, adjusted   770
Mandatory Exchangeable Bonds (mark-to-market) -105 -85
Contingent Value Rights (mark-to-market) 5 5
Earnings 2011 according to
U.S. GAAP
  690

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2011, adjusted   770
Mandatory Exchangeable Bonds (mark-to-market) -105 -85
Contingent Value Rights (mark-to-market) 5 5
Earnings 2011 according to
U.S. GAAP
  690

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2010, adjusted   660
Mandatory Exchangeable Bonds (mark-to-market) -98 -70
Contingent Value Rights (mark-to-market) 32 32
Earnings 2010 according to
U.S. GAAP
  622

€ in millions Other financial result Net income attributable to Fresenius SE & Co. KGaA
Earnings 2010, adjusted   660
Mandatory Exchangeable Bonds (mark-to-market) -98 -70
Contingent Value Rights (mark-to-market) 32 32
Earnings 2010 according to
U.S. GAAP
  622

For further information regarding Mandatory Exchangeable Bonds and Contingent Value Rights see note 10, Other financial result.

Continue reading:
4. Sales

QUICKFINDER

History

Tools